This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

A Trial With Schizophrenic Patients

Daniel P. van Kammen, MD, PhD; John P. Docherty, MD; Stephen R. Marder, MD; S. Charles Schulz, MD; William E. Bunney, Jr, MD

Arch Gen Psychiatry. 1980;37(3):287-290.

Abstract
• The dopamine hypothesis of schizophrenia claims that increased dopamine activity underlies psychotic behavior. This hypothesis gets major support from the reported d-amphetamine-induced worsening of psychosis, because amphetamine increases dopamine activity in the brain. Dopamine receptor supersensitivity has been shown to be present in animals during the postneuroleptic period. In this study the postulated relationships between psychotic decompensation as observed after d-amphetamine infusion and the dopamine receptor supersensitivity expected to be present during the neuroleptic withdrawal period were examined. Twenty milligrams of d-amphetamine administered intravenously did not cause a stronger psychotogenic effect in 12 schizophrenic patients. One week after discontinuation of pimozide treatment, the d-amphetamine-induced change as indicated by the Brief Psychiatric Rating Scale (BPRS) paranoid disturbance cluster score, was not significantly different from the response to a similar infusion during the drug-free state. Unexpectedly, the increase in the BPRS mannerisms and posturing item and in the pulse rate response to d-amphetamine were decreased. These results raise questions about the role of dopamine in d-amphetamine effects and suggest postneuroleptic dopamine receptor subsensitivity. They challenge a simple dopamine hypothesis of schizophrenia.

Author Affiliations
From the Section of Neuropsychopharmacology, Biological Psychiatry Branch, National Institute of Mental Health, Bethesda, Md. Dr Docherty is currently with the Yale Psychiatric Institute, New Haven, Conn. Dr Marder is currently with the Veterans Administration Hospital—Brentwood, Los Angeles.

Footnotes
Accepted for publication Aug 30, 1979.

Read in part before the annual meeting of the American College of Neuropsychopharmacology, Maui, Hawaii, Dec 18, 1978.

Reprint requests to Biological Psychiatry Branch, National Institute of Mental Health, Bldg 10, Rm 4N214, 9000 Rockville Pike, Bethesda, MD 20205 (Dr Van Kammen).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Stimulant psychosis: systematic review
Curran et al.
Br. J. Psychiatry 2004;185:196-204.
ABSTRACT | FULL TEXT  

Does the Dexamethasone Suppression Test Relate to Subtypes, Factors, Symptoms, or Severity?
Miller and Nelson
Arch Gen Psychiatry 1987;44:769-774.
ABSTRACT  

Antipsychotic Effects of Pimozide in Schizophrenia: Treatment Response Prediction With Acute Dextroamphetamine Response
van Kammen et al.
Arch Gen Psychiatry 1982;39:261-266.
ABSTRACT  

Long-term Pimozide Pretreatment Differentially Affects Behavioral Responses to Dextroamphetamine in Schizophrenia: Further Exploration of the Dopamine Hypothesis of Schizophrenia
van Kammen et al.
Arch Gen Psychiatry 1982;39:275-281.
ABSTRACT